2023 Tuberculosis Drug Discovery and Development Gordon Research Conference and Gordon Research Seminar

2023结核病药物发现与开发戈登研究大会暨戈登研究研讨会

• 批准号: 10675238
• 负责人: Dirk Schnappinger
• 金额: $ 0.6万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-11 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10675238
• 关键词: Address; Architecture; Area; Automobile Driving; Bacterial Infections; Biology; Budgets; COVID-19; Cessation of life; Chemicals; Clinical; Clinical Trials; Clinical Trials Design; Collaborations; Communicable Diseases; Communities; Complex; Country; Coupled; Data; Development; Disclosure; Disease; Drug Combinations; Drug Industry; Drug resistance; Drug resistance in tuberculosis; Environment; Evaluation; Face; Faculty; Fostering; Funding Agency; Geography; Goals; Growth; Health Priorities; Hour; Human; Income; Industrialization; Infectious Agent; Injectable; Institution; International; Lead; Learning; Leisures; Location; Mentors; Methods; Multidrug-Resistant Tuberculosis; Mycobacterium tuberculosis; Oral; Participant; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Play; Postdoctoral Fellow; Privatization; Regimen; Research; Research Personnel; Science; Scientist; Series; Site; Socialization; Spain; Speed; Structure; Students; Technology; Time; Training; Translational Research; Tuberculosis; Underrepresented Minority; United States National Institutes of Health; Woman; career; career development; design; drug development; drug discovery; drug efficacy; drug-sensitive; early-career faculty; fighting; global health; improved; innovation; insight; meetings; new technology; next generation; novel; novel strategies; novel therapeutics; pandemic disease; premature; prevent; programs; research study; side effect; success; symposium; tuberculosis chemotherapy; tuberculosis drugs; tuberculosis treatment

ABSTRACT This application seeks support for the 2023 Tuberculosis (TB) Drug Discovery & Development Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held in at the Rey Don Jaime Grand Hotel in Castelldefels, Spain from July 22-23 and July 23 – 28, 2023. This will be the eleventh GRC on TB Drug discovery (with the first being held in 2001 and thereafter on a biennial basis) and the fifth GRS associated with this GRC. For more than 20 years this conference series has held a unique place in the global portfolio of TB research conferences. For many years it has been oversubscribed, been rated above average by more than 70% of attendees and received a high-performance rating in the GRC Evaluation. Among the factors that makes this conference series stand out are its rigorous focus on TB drug development, the emphasis on presentation of unpublished data (enabled by the strictly enforced rules against recording or photographing of presentations), the disclosure of novel hit and lead compounds, the large fraction of attendees from the pharmaceutical industry, and the well-attended networking sessions. The overall theme for this GRC is “Leads, technologies and clinical trials for new TB drug regimens”. The conference will discuss and disclose recently developed lead molecules as well as new technologies and approaches to clinical trials, debate how recent insight into TB biology and performance of clinical drug combinations may facilitate identifying leads and improving regimens, review how new technologies and trial innovations can identify improved drug regimens, and discuss how to capitalize on successes in other disease areas. The focus of this conference is thus quite different from the most recent conference in this series, which centered around treatment shortening and was held in 2019. The GRC and associated GRS foster an environment wherein which researchers are encouraged to share cutting edge unpublished data and exchange ideas between both established and young investigators and trainees hereby promoting career development for all attendees. The GRC will include a “Power Hour”, an optional gathering for all meeting participants to address the challenges underrepresented minorities and women face in science and to support their professional growth. Both the GRC and the GRS programs will reflect the diversity of the scientists in the field with an aim of strong representation of women, underrepresented minorities, and international scientists. GRCs are unique in facilitating multiple opportunities for informal interactions between researchers from different sectors, geographies, and career stages, often resulting in exchanges leading to new collaborations. In this pandemic era, such opportunities have become rare and thus even more important to driving forward innovation in research.

摘要 该申请寻求对2023年结核病（TB）药物发现和开发戈登研究的支持 会议（GRC）和戈登研究研讨会（GRS）将在雷伊唐海梅大酒店举行， Castelldefels，西班牙，2023年7月22日至23日和7月23日至28日这将是结核病药物发现的第十一次GRC (with第一次于2001年举行，其后每两年举行一次），以及与本研讨会有关的第五次研讨会。 20多年来，这一系列会议在全球结核病研究领域占有独特的地位 两会多年来，它一直被超额认购，超过70%的人认为它高于平均水平。 并在GRC评估中获得了高绩效评级。在这些因素中， 会议系列突出的是其严格的重点是结核病药物的开发，重点介绍 未发布的数据（通过严格执行禁止录制或拍摄演示文稿的规则）， 新的命中和先导化合物的公开，来自制药工业的大部分与会者， 以及出席率很高的网络会议。 本次研讨会的总体主题是“新型结核病药物治疗方案的先导、技术和临床试验”。的 会议将讨论和披露最近开发的铅分子以及新技术， 临床试验的方法，争论最近对结核病生物学的认识和临床药物的性能 联合用药可能有助于识别先导药物和改善治疗方案，审查新技术和试验 创新可以确定改进的药物治疗方案，并讨论如何利用在其他疾病中的成功， 地区因此，本次会议的重点与本系列中最近的一次会议大不相同， 以缩短治疗时间为中心，于2019年举行。 GRC和相关的GRS营造了一个鼓励研究人员分享的环境 尖端未发表的数据和交流思想之间的既定和年轻的研究人员， 学员借此促进所有与会者的职业发展。GRC将包括一个“电源小时”， 所有与会者可选择参加的聚会，以应对代表性不足的少数群体和妇女面临的挑战 面对科学，并支持他们的专业成长。GRC和GRS计划都将反映 该领域科学家的多样性，目标是妇女、代表性不足的少数民族、 国际科学家。GRCs在促进非正式互动的多种机会方面是独一无二的 来自不同部门、地理位置和职业阶段的研究人员之间进行交流， 导致新的合作。在这个大流行的时代，这样的机会已经变得罕见， 这对推动研究创新至关重要。